Rett Syndrome Market Sees Momentum with Novel Gene and Protein-Targeted Therapies
Rett syndrome market dynamics are expected to undergo significant shifts as more targeted therapies, including gene therapies and pharmacological interventions, enter clinical development and regulatory approval stages. Additionally, increased awareness, improved diagnostic methods, and collaborative efforts within the healthcare community may drive Rett syndrome market expansion and accessibility to treatments for affected individuals.
LAS VEGAS, May 26, 2025 /PRNewswire/ -- Rett syndrome is a rare genetic neurological condition that typically emerges in infancy and primarily affects girls, though occasional cases have been observed in boys. The disorder causes profound impairments that impact nearly all aspects of a person's life.
It is the second leading cause of severe intellectual disability in females. During the stage of developmental regression, many individuals with Rett syndrome also meet the diagnostic criteria for autism spectrum disorder (ASD). The condition mostly affects females because it is linked to mutations on the X chromosome. Females have two X chromosomes, which can provide some genetic compensation, whereas males, who have only one X chromosome, are less likely to survive if the MECP2 gene is mutated.
There is no known cure for Rett syndrome, and treatment focuses on symptom management through a comprehensive, multidisciplinary approach. Care often involves coordination among various specialists, including pediatricians, pediatric neurologists, gastroenterologists, speech therapists, psychiatrists, nutritionists, and others, to address the child's complex needs. Genetic counseling can also be helpful for patients and their families. Rett syndrome treatment typically includes physical therapy, occupational therapy, speech and language therapy, nutritional support, and medications.
Learn more about the Rett syndrome treatment @ New Treatment for Rett Syndrome
In March 2023, the US FDA approved Acadia Pharmaceuticals' DAYBUE (trofinetide) as the first treatment for Rett syndrome in both adults and children aged two years and older. Trofinetide is a synthetic analog of a naturally occurring tripeptide called glycine-proline-glutamate (GPE).
While the precise therapeutic mechanism of trofinetide in Rett syndrome remains unclear, animal studies have shown that it can promote dendritic branching and enhance synaptic plasticity. The medication is administered either orally or through a gastrostomy tube, taken twice daily—morning and evening—with or without food.
Other Rett syndrome treatments, such as bromocriptine and carbidopa-levodopa (dopamine agonists), have been explored to manage motor symptoms in Rett syndrome, though their effectiveness tends to be limited and short-lived. Some evidence suggests levocarnitine may offer benefits in certain cases. For patients with gastroesophageal reflux (GER), antireflux medications like metoclopramide may be helpful, and anti-epileptic drugs are often used to manage seizure-like episodes. While none of these treatments offer a cure, they can help alleviate symptoms such as seizures, breathing irregularities, abnormal heart rhythms, indigestion, and constipation.
Find out more on FDA-approved Rett syndrome drugs @ Rett Syndrome Treatment Options
The pipeline for Rett syndrome is continuously evolving with ongoing research and clinical trials focusing on innovative approaches to improve outcomes and reduce side effects. Current areas of interest in the pipeline include targeted therapies, gene therapies, and others.
Thus, the pipeline for Rett syndrome looks promising, with a range of novel therapies such as NA-921 (Bionetide) (Biomed Industries), NGN-401 (NEUROGENE), TSHA-102 (Taysha Gene Therapies), ANAVEX2-73(BLARCAMESINE) (Anavex Lifesciences), and others, and approaches under investigation that have the potential to redefine Rett syndrome treatment standards and improve patient outcomes in the future.
Discover which therapies are expected to grab major Rett syndrome market share @ Rett Syndrome Market Report
ANAVEX2-73 (blarcamesine), developed by Anavex Life Sciences, is an experimental oral treatment aimed at restoring normal brain signaling in individuals with Rett syndrome by activating the sigma-1 receptor (SIGMAR1), a key brain protein. The drug is currently being assessed in two clinical trials:
The AVATAR study, a Phase III double-blind, randomized, placebo-controlled trial in adults (18+) with Rett syndrome. This study evaluates the drug's safety, tolerability, and efficacy using a range of clinical, molecular, and biochemical endpoints.
The EXCELLENCE study, which is investigating its effects in pediatric patients aged 5–17 years.
Results from an earlier Phase II trial in adult patients indicated behavioral improvements that persisted for several months during an extension phase. ANAVEX2-73 has received Fast Track, Rare Pediatric Disease, and Orphan Drug designations from both the FDA and the European Union.
NGN-401, being developed by Neurogene, is an investigational one-time gene therapy for Rett syndrome based on an AAV9 vector. It is the first clinical candidate to deliver the full-length human MECP2 gene using Neurogene's proprietary EXACT™ technology, which precisely controls gene expression levels. This regulation is critical for treating Rett syndrome, as excessive MECP2 expression can lead to toxicity, a challenge for traditional gene therapies.
Neurogene is currently conducting a Phase I/II clinical trial for NGN-401. In April 2025, the company published peer-reviewed research in Science Translational Medicine showcasing the ability of EXACT to maintain MECP2 expression at safe and therapeutic levels in preclinical Rett models. These findings supported the launch of their ongoing clinical trial.
NGN-401 has received Fast Track, Rare Pediatric Disease, and Orphan Drug status from the FDA, along with Orphan and Advanced Therapy Medicinal Product designations from the EMA and Innovative Licensing and Access Pathway (ILAP) designation from the UK's MHRA.
TSHA-102 is an experimental gene therapy delivered intrathecally using a self-complementary AAV9 vector, currently being studied for the treatment of Rett syndrome. Intended as a one-time therapy, it targets the underlying genetic cause of the disorder by introducing a functional MECP2 gene into cells of the central nervous system (CNS). The therapy features an innovative miRNA-Responsive Auto-Regulatory Element (miRARE) technology, which helps regulate MECP2 expression in individual CNS cells, minimizing the risk of overexpression.
TSHA-102 has been granted multiple regulatory designations, including Regenerative Medicine Advanced Therapy, Fast Track, Orphan Drug, and Rare Pediatric Disease designations from the FDA, Orphan Drug designation from the European Commission, and an Innovative Licensing and Access Pathway designation from the UK's Medicines and Healthcare products Regulatory Agency.
NA-921 (Bionetide) is an orally administered small molecule currently in Phase III clinical trials for treating Rett syndrome. Its ability to efficiently cross the blood-brain barrier allows it to be effective at low doses. In March 2025, Biomed Industries announced the results of its Phase II/III clinical trials. The topline data confirmed strong evidence of both safety and efficacy. A comparative analysis of side effects revealed that NA-921 has a significantly better safety and tolerability profile than DAYBUE, a drug marketed by Acadia Pharmaceuticals, Inc. These results position NA-921 as a promising new treatment option, with reduced side effects and higher patient adherence.
Discover more about drugs for Rett syndrome in development @ Rett Syndrome Clinical Trials
The anticipated launch of these emerging therapies for Rett syndrome are poised to transform the market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the Rett syndrome market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
DelveInsight estimates that the market size for Rett syndrome is expected to grow at a significant CAGR by 2034. The Rett syndrome market is estimated to change significantly for the forecast period 2025–2034. Major Rett syndrome market drivers, such as rising prevalence, technological advancements, and upcoming therapies, will boost the Rett syndrome market significantly.
DelveInsight's latest published market report, titled as Rett Syndrome Market Insight, Epidemiology, and Market Forecast – 2034, will help you to discover which market leader is going to capture the largest market share. The report provides comprehensive insights into the Rett syndrome country-specific treatment guidelines, patient pool analysis, and epidemiology forecast to help understand the key opportunities and assess the market's underlying potential. The Rett syndrome market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
Total Rett Syndrome Diagnosed Prevalent Cases
Rett Syndrome Gender-Specific Diagnosed Prevalent Cases
Rett Syndrome Age-specific Diagnosed Prevalent Cases
Rett Syndrome Treated Cases
The report provides an edge while developing business strategies by understanding trends shaping and driving the 7MM Rett syndrome market. Highlights include:
10-year Forecast
7MM Analysis
Epidemiology-based Market Forecasting
Historical and Forecasted Market Analysis upto 2034
Emerging Drug Market Uptake
Peak Sales Analysis
Key Cross Competition Analysis
Industry Expert's Opinion
Access and Reimbursement
Download this Rett syndrome market report to assess the epidemiology forecasts, understand the patient journeys, know KOLs' opinions about the upcoming treatment paradigms, and determine the factors contributing to the shift in the Rett syndrome market. Also, stay abreast of the mitigating factors to improve your market position in the Rett syndrome therapeutic space.
Related Reports
Rett Syndrome Epidemiology Forecast
Rett Syndrome Epidemiology Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted Rett syndrome epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Rett Syndrome Pipeline
Rett Syndrome Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Rett syndrome companies, including Anavex Life Sciences Corp, Neurogene, Taysha GTx, among others.
Angelman Syndrome Market
Angelman Syndrome Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Angelman syndrome companies, including GeneTx Biotherapeutics, GEXVal, Ionis Pharmaceuticals, Neuren Pharmaceuticals, Ovid Therapeutics, PTC Therapeutics, Roche, Sarepta Therapeutics, StrideBio, Taysha Gene Therapies, Ultragenyx Pharmaceutical, among others.
Angelman Syndrome Pipeline
Angelman Syndrome Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Angelman syndrome companies, including Neuren Pharmaceuticals, Ultragenyx Pharmaceutical, Ionis Pharmaceuticals, Roche, GEXVal, PTC Therapeutics, Taysha Gene Therapies, Ovid Therapeutics, among others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact Us
Shruti Thakur info@delveinsight.com +14699457679
Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/rett-syndrome-market-sees-momentum-with-novel-gene-and-protein-targeted-therapies--delveinsight-302464999.html
SOURCE DelveInsight Business Research, LLP
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
12 minutes ago
- Yahoo
NUTEX HEALTH ANNOUNCES INTERNET AVAILABILITY OF PROXY MATERIALS FOR ITS 2025 ANNUAL MEETING
HOUSTON, June 2, 2025 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ: NUTX), a physician-led, integrated healthcare delivery system comprised of 24 state-of-the-art micro hospitals and hospital outpatient departments (HOPDs) in 11 states and primary care-centric, risk-bearing physician networks, today announced the availability of its definitive proxy materials for its 2025 annual meeting to be held on July 14, 2025 at 10:00 am Central Time via the internet as a virtual meeting only (and not in person) at We look forward to hosting you at our virtual shareholder meeting and encourage you to participate and vote. Commencing June 2, 2025, we are mailing the Notice of Internet Availability of Proxy Materials, as specified below. For its 2025 Annual Meeting, the Company has chosen to use the "notice only" option for the delivery of proxy materials. This means that at least 40 days before the annual meeting date, we are mailing the notice to you or your bank, broker, trustee or other intermediary and then your bank, broker, trustee or other intermediary will mail to you such "Notice Regarding the Availability of Proxy Materials." The notice contains important information about accessing the annual meeting proxy materials and voting your shares. The Company's stockholders will not receive a paper set of annual meeting proxy materials, unless they request the proxy materials in paper form using the instructions printed on the notice. Stockholders may view our definitive proxy statement dated June 2, 2025 and our Form 10-K online OR may receive a free paper or email copy of the material(s) by following the instructions in their notice. As specified in the notice, if a stockholder of the Company would like to request a copy of the material(s) for the Company's 2025 Annual Meeting, the stockholder may (1) visit (2) call 1-800-579-1639 or (3) send an email to sendmaterial@ If sending an email, the stockholder must include the control number that is indicated in the notice in the subject line. About Nutex Health Inc. Headquartered in Houston, Texas and founded in 2011, Nutex Health Inc. (NASDAQ: NUTX) is a healthcare management and operations company with two divisions: a Hospital Division and a Population Health Management Division. The Hospital Division owns, develops and operates innovative health care models, including micro-hospitals, specialty hospitals, and hospital outpatient departments (HOPDs). This division owns and operates 24 facilities in 11 states. The Population Health Management division owns and operates provider networks such as Independent Physician Associations (IPAs). Through our Management Services Organization (MSO), we provide management, administrative and other support services to our affiliated hospitals and physician groups. Forward-Looking Statements Certain statements and information included in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Act of 1995. When used in this press release, the words or phrases "will", "will likely result," "expected to," "will continue," "anticipated," "estimate," "projected," "intend," "goal," or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks, known and unknown, and uncertainties, many of which are beyond the control of the Company. Such uncertainties and risks include, but are not limited to, our ability to successfully execute our growth strategy, changes in laws or regulations, including the interim final and final rules implemented under the No Surprises Act, economic conditions, dependence on management, dilution to stockholders, lack of capital, the effects of rapid growth upon the Company and the ability of management to effectively respond to the growth and demand for products and services of the Company, newly developing technologies, the Company's ability to compete, conflicts of interest in related party transactions, regulatory matters, protection of technology, lack of industry standards, the effects of competition and the ability of the Company to obtain future financing. An extensive list of factors that can affect future results are discussed in the Annual Report on Form 10-K for the year ended December 31, 2024, and subsequent Quarterly Report on Form 10-Q for the three months ended March 31, 2025 under the heading "Risk Factors" in Part II, Item IA thereof, and other documents filed from time to time with the Securities and Exchange Commission. Such factors could materially adversely affect the Company's financial performance and could cause the Company's actual results for future periods to differ materially from any opinions or statements expressed within this press release. View original content: SOURCE Nutex Health, Inc. Sign in to access your portfolio
CBS News
16 minutes ago
- CBS News
San Francisco Marina District close to having new transitional-housing facility
A recovery housing facility proposed in San Francisco's Marina District is closer to moving one step closer to final approval. It's a part of the mayor's plans to open hundreds of new beds for homeless people struggling with addiction. Steve Adami spent two decades in and out of prison, struggling to escape a vicious cycle of drug addiction and crime. Looking at a California Corrections picture of himself, he reflected on how far he has come in his journey. "It's someone I don't recognize anymore. It was definitely somebody who needed a lot of help and support to get his life together, and that's what I got," said Adami. Tackling San Francisco's drug and homelessness crisis is now Adami's mission as executive director of The Salvation Army's The Way Out program. "Areas of the city have been overrun by public drug use, open-air drug markets and crime. I don't want that model in my neighborhood either. But that's not the model we're proposing at the Marina Inn," said Adami. The recovery housing facility, providing 68 beds at Octavia and Lombard Street in the Marina District, will be operated by The Salvation Army in partnership with the city's Department of Public Health. It's an abstinence-based, two-year transitional housing program for people who have already completed long-term drug treatment "This model program has not been the type of program San Francisco has used in the past," said Adami. Everyone is required to work, save money and get drug tested. "Sadly, many of the residents of this faculty will relapse. Statistics just show that's the case. When they do, they're now in our neighborhood," said San Francisco resident Maurice Fitzgerald, who lives in the Marina District. While many residents believe drug-free transitional housing can help clean up city streets and even help nearby businesses, others like Fitzgerald say they're concerned about relapses and participants who have criminal backgrounds. "We have concerns this will increase car break-ins and that desperate drug addicts will do whatever they need to do to find money to get their fix," said Fitzgerald. Adami and other city officials said sex offenders, arsonists, and people who have committed crimes against children won't be allowed. Garrett Collard is a resident at a similar recovery housing program. He said he would be back on the streets if it weren't for the Salvation Army's pilot program. "You're just right back where you started. You go six months and are clean, but if you have nowhere else to go or stay in another program or go to a sober living environment, you're back on the streets," said Collard. Adami points to participants like Collard and to recovering addicts like himself as reasons to support the city's Break the Cycle initiative, aiming to add hundreds of new treatment and recovery beds across the city. "The current administration and the Department of Public Health and Department of Homelessness are implementing new abstinence-based strategies because they're proven to be effective," said Adami. It's programs like this that are giving Adami hope others can follow in his footsteps too. The city has announced plans to open nearly 300 treatment and interim housing beds at five sites across the city by the end of summer. It's part of the mayor's Break the Cycle initiative to add 1,500 beds citywide for homeless people and those struggling with mental illness and addiction.
CBS News
26 minutes ago
- CBS News
Texas lawmakers approve historic new $100 million for child care
The 2025 Texas legislative session is ending with a historic investment in child care. Legislators agreed to add $100 million in new funding for child care scholarships that benefit working families and employers. U.S. Department of Labor "In Tarrant County, an average family can expect to spend 12% of their income on child care," said Stacy Agee Martin, executive director of Fortress, an early childhood development center in Fort Worth. "But for a family in poverty, a low-income earning family, that creeps closer to 35%, which makes it pretty obvious why people say, 'I can't afford to work.'" Thousands still on waitlist Currently, nearly 100,000 children in Texas are on a waitlist for state financial assistance to help cover child care costs. "About 90% of the families we serve are on the waitlist for that subsidy, which means Fortress has been filling that gap through funders and grants," Martin said. Relief for working families That's why she welcomed the news that lawmakers are allocating $100 million to expand access to child care scholarships. "I'm grateful," she said. "I'm excited about what this is going to do for our low-income families that are working so hard and who want to work." Advocates, businesses drove change The investment is the result of a coordinated effort by advocates, families, and private businesses to push for solutions during the session. "This is a historic day," said David Feigen, director of early learning policy at Texans Care for Children. "The state has never committed new funding in the budget for child care like this before. This is $100 million in new dollars for the child care services program, which helps working parents get scholarships that allow them to go to work. Their children are enrolled in really high-quality programs. So this is a huge step." Child care crisis impacts all Feigen said the move reflects growing recognition of the wide-reaching impact of the child care crisis. "This child care crisis impacts every Texan across the state," he said. "Whether you are relying on child care or not, you're probably relying on people who are relying on child care every single day. The more families that have access to this needed service, the more who can show up to work every day and support every aspect of our economy." Billions lost to inaction Studies show child care issues cost Texas more than $11 billion annually in lost productivity and revenue. "We all think of child care as an education issue, a family issue, a women's issue," said Kelsey Erickson Streufert, chief public affairs officer at the Texas Restaurant Association. "It is all of those things, but it is also really crippling our workforce and our businesses' ability to keep and attract the talent they need to keep the Texas miracle alive and continue to serve our state's growing population." Employers Join Advocacy Efforts The Texas Restaurant Association, in partnership with Early Matters Texas, the Texas Association of Business, and Texas 2036, launched the Employers for Childcare Task Force (E4C) to advocate for legislative change. Policy Changes Support Providers The coalition supported bills to create a free online resource hub for employers about child care, allow state agencies to share child care-related data, and prioritize subsidies for child care workers to help cover their own child care needs. "We want them to be at the front of the line, because if you can keep them in the classroom, then they can serve so many other families in the workforce," Streufert said. "That's another example of a policy we supported to address this challenge for working families." Funding Helps, But Not Enough While advocates say the $100 million investment is a major step forward, they also stress that it's only the beginning. "That's a lot of money, but it just meets the gap that's already there — and barely," Martin said. More Than 95,000 Still Waiting E4C estimates the funding will help serve about 10,000 additional children across the state. More than 95,000 remain on the waitlist. "Child care is such a huge need in our state that we want to be very clear this session was not a silver bullet," Streufert said. "We accomplished great things this session, but we have a long way to go. In fact, some of our biggest accomplishments this session really set the stage for the long-term conversations we need to really address this problem."
